Net profit of Epigral rose 87.13% to Rs 160.69 crore in the quarter ended June 2025 as against Rs 85.87 crore during the previous quarter ended June 2024. Sales declined 6.86% to Rs 606.54 crore in the quarter ended June 2025 as against Rs 651.20 crore during the previous quarter ended June 2024.